Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.40 |
| ▸ | PTPN1 | P18031 | 4/20 | 0.39 |
| ▸ | FURIN | P09958 | 2/20 | 0.39 |
| ▸ | SSTR3 | P32745 | 1/20 | 0.38 |
| ▸ | CASP3 | P42574 | 2/20 | 0.38 |
| ▸ | SIRT2 | Q8IXJ6 | 5/20 | 0.38 |
| ▸ | SIRT1 | Q96EB6 | 3/20 | 0.38 |
| ▸ | SIRT3 | Q9NTG7 | 3/20 | 0.38 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.37 |
| ▸ | SIRT5 | Q9NXA8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12944195 | 1.00 | HTR2A (0.40) | HTR2APTPN1FURINSSTR3CASP3 | |
| SCHEMBL29414597 | 1.00 | HTR2A (0.40) | HTR2APTPN1FURINSSTR3CASP3 | |
| SCHEMBL29579452 | 1.00 | HTR2A (0.40) | HTR2APTPN1FURINSSTR3CASP3 | |
| SCHEMBL13110590 | 1.00 | HTR2A (0.40) | HTR2APTPN1FURINSSTR3CASP3 | |
| SCHEMBL19731720 | 1.00 | HTR2A (0.40) | HTR2APTPN1FURINSSTR3CASP3 | |
| SCHEMBL2734925 | 1.00 | HTR2A (0.40) | HTR2APTPN1FURINSSTR3CASP3 | |
| SCHEMBL13830646 | 1.00 | HTR2A (0.40) | HTR2APTPN1FURINSSTR3CASP3 | |
| Trifluoroacetic Acid SCHEMBL31096968 | 0.96 | PTPN1 (0.43) | HTR2APTPN1FURINSSTR3CASP3 | |
| SCHEMBL15088221 | 0.96 | HTR2A (0.40) | HTR2APTPN1SSTR3SIRT2SIRT1 | |
| SCHEMBL13311064 | 0.94 | FURIN (0.39) | HTR2APTPN1FURINSSTR3SIRT2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8952147-B2 | Conjugates, preparation thereof, and therapeutic use thereof | SANOFI (FR) | 2015-02-10 | — | — | US | disclosed |
| US-20120225089-A1 | NOVEL CONJUGATES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120225089-A1 | NOVEL CONJUGATES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | ERG28, CARS1, FOLH1 | HTR2A 4301/4885PTPN1 3942/4885FURIN 535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.